Fidelity Investments
KROS icon

Fidelity Investments’s Keros Therapeutics KROS Stock Holding History

Fidelity Investments’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$378K Buy
35,328
+2,654
+8% +$29.6K ﹤0.01% 3400
2026
Q1 		$361K Sell
32,674
-2,923
-8% -$45.1K ﹤0.01% 3247
2025
Q4 		$725K Sell
35,597
-64,934
-65% -$1.14M ﹤0.01% 2963
2025
Q3 		$1.59M Sell
100,531
-63,740
-39% -$942K ﹤0.01% 2630
2025
Q2 		$2.19M Sell
164,271
-277,269
-63% -$3.74M ﹤0.01% 2457
2025
Q1 		$4.5M Sell
441,540
-5,101,768
-92% -$59.2M ﹤0.01% 2186
2024
Q4 		$87.8M Buy
5,543,308
+644,174
+13% +$33.5M 0.01% 1172
2024
Q3 		$284M Buy
4,899,134
+179,374
+4% +$8.86M 0.02% 688
2024
Q2 		$216M Sell
4,719,760
-298,756
-6% -$16.1M 0.01% 758
2024
Q1 		$332M Buy
5,018,516
+1,144,312
+30% +$67.9M 0.02% 590
2023
Q4 		$154M Buy
3,874,204
+269,276
+7% +$8.44M 0.01% 851
2023
Q3 		$115M Sell
3,604,928
-454,113
-11% -$17M 0.01% 912
2023
Q2 		$163M Buy
4,059,041
+7,168
+0.2% +$314K 0.01% 804
2023
Q1 		$173M Buy
4,051,873
+372,784
+10% +$18.8M 0.02% 766
2022
Q4 		$177M Sell
3,679,089
-184,437
-5% -$8.62M 0.02% 737
2022
Q3 		$145M Buy
3,863,526
+263,631
+7% +$9.14M 0.02% 806
2022
Q2 		$99.5M Buy
3,599,895
+591,959
+20% +$26M 0.01% 974
2022
Q1 		$164M Sell
3,007,936
-496,862
-14% -$25.5M 0.01% 861
2021
Q4 		$205M Buy
3,504,798
+4,119
+0.1% +$205K 0.02% 798
2021
Q3 		$138M Buy
3,500,679
+6,140
+0.2% +$219K 0.01% 969
2021
Q2 		$148M Buy
3,494,539
+566,422
+19% +$30.7M 0.01% 938
2021
Q1 		$180M Buy
2,928,117
+283,497
+11% +$18M 0.02% 827
2020
Q4 		$187M Buy
2,644,620
+856,075
+48% +$53.9M 0.02% 772
2020
Q3 		$69M Buy
1,788,545
+428,873
+32% +$17M 0.01% 1079
2020
Q2 		$51M Buy
+1,359,672
New +$41.9M 0.01% 1155

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Fidelity Investments's KROS Position: Q2 2026 in Review

Fidelity Investments increased its Keros Therapeutics (KROS) stake by 8.1% in Q2 2026, buying an estimated $29.6K and bringing the position to 35,328 shares worth $378K. The position accounts for ﹤0.01% of the portfolio, ranked #3400.

Fidelity Investments first reported a position in KROS in Q2 2020 and has held it in 25 quarters since. The position peaked at $332M in Q1 2024. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Fidelity Investments held 35,328 shares of Keros Therapeutics worth $378K as of Q2 2026.
  • Fidelity Investments bought 2,654 Keros Therapeutics shares in Q2 2026, an estimated $29.6K.
  • Keros Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #3400 holding.
  • Fidelity Investments first reported a position in Keros Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Fidelity Investments's Keros Therapeutics position peaked at $332M in Q1 2024.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.